Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908598 | 0.85 | NOTUM (0.54) | NOTUMHSP90AA1PIN1CYP19A1KDM1A | |
| SCHEMBL2583097 | 0.84 | NOTUM (0.55) | NOTUMHSP90AA1PIN1CYP19A1IDO1 | |
| SCHEMBL23603985 | 0.82 | NOTUM (0.59) | NOTUMKDM1A | |
| SCHEMBL13160180 | 0.80 | NOTUM (0.51) | NOTUMKCNH2 | |
| SCHEMBL13183607 | 0.80 | NOTUM (0.53) | NOTUM | |
| SCHEMBL13469380 | 0.78 | NOTUM (0.59) | NOTUMHSP90AA1PIN1MAPKAPK2KDM1A | |
| SCHEMBL9729936 | 0.78 | FLT3 (0.46) | NOTUM | |
| SCHEMBL13119830 | 0.78 | P2RX7 (0.50) | NOTUM | |
| SCHEMBL19589440 | 0.76 | MAOA (0.50) | NOTUMKCNH2 | |
| SCHEMBL20046658 | 0.75 | RXRA (0.41) | NOTUMKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | NOTUM 2481/4885HSP90AA1 4118/4885PIN1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.